Sprintome
@sprintome.bsky.social
AI + Drug Discovery | Your front-row seat to the future of medicine
https://sprintome.substack.com
https://sprintome.substack.com
Pinned
Sprintome
@sprintome.bsky.social
· Apr 18
AI is no longer just a tool in the lab — it's becoming the lab.
At NVIDIA #GTC, the future of drug discovery was laid bare: computational, agentic, and lightning fast. Here's what you need to know 👇
At NVIDIA #GTC, the future of drug discovery was laid bare: computational, agentic, and lightning fast. Here's what you need to know 👇
Windward Bio signs second China deal in 2021, obtaining a bispecific drug candidate from Qyuns for respiratory and dermatology conditions. The Swiss biotech aims to diversify its pipeline with this strategic move.
December 23, 2025 at 10:01 PM
Windward Bio signs second China deal in 2021, obtaining a bispecific drug candidate from Qyuns for respiratory and dermatology conditions. The Swiss biotech aims to diversify its pipeline with this strategic move.
Ipsen strikes a deal with Simcere Zaiming, paying $45M upfront for an ADC license outside Greater China. This move further diversifies Ipsen's oncology portfolio, enhancing its global presence.
December 23, 2025 at 8:01 PM
Ipsen strikes a deal with Simcere Zaiming, paying $45M upfront for an ADC license outside Greater China. This move further diversifies Ipsen's oncology portfolio, enhancing its global presence.
AstraZeneca's ceralasertib phase 3 trial falls short, missing primary endpoint. This hampers the use of synthetic lethal mechanism to combat immuno-oncology drug resistance.
December 23, 2025 at 1:00 PM
AstraZeneca's ceralasertib phase 3 trial falls short, missing primary endpoint. This hampers the use of synthetic lethal mechanism to combat immuno-oncology drug resistance.
💰 Atavistik raises an impressive $120M in latest funding round, showcasing strong investor confidence. Meanwhile, Syneron Bio also locks in new funds to support its innovative biotech initiatives.
December 22, 2025 at 10:01 PM
💰 Atavistik raises an impressive $120M in latest funding round, showcasing strong investor confidence. Meanwhile, Syneron Bio also locks in new funds to support its innovative biotech initiatives.
CMS introduces two mandatory payment models in Medicare to cut drug prices. These initiatives are a continuation of Trump's 'most favored nation' plan. Industry resistance anticipated due to the focus on lowering drug costs.
December 22, 2025 at 8:01 PM
CMS introduces two mandatory payment models in Medicare to cut drug prices. These initiatives are a continuation of Trump's 'most favored nation' plan. Industry resistance anticipated due to the focus on lowering drug costs.
💰 Ipsen strikes $1B deal to acquire Simcere's preclinical LRRC15-targeting asset, bolstering its presence in the ADC space. The French biopharma is making significant moves to catch up with competitors.
December 22, 2025 at 1:00 PM
💰 Ipsen strikes $1B deal to acquire Simcere's preclinical LRRC15-targeting asset, bolstering its presence in the ADC space. The French biopharma is making significant moves to catch up with competitors.
Syremis Therapeutics, founded by Teva alums and Karuna's team, raises $165M in series A funding for a dual M1/M4 agonist in schizophrenia. The biotech aims to advance neuropsychiatric treatments with this substantial financial backing.
December 21, 2025 at 10:00 PM
Syremis Therapeutics, founded by Teva alums and Karuna's team, raises $165M in series A funding for a dual M1/M4 agonist in schizophrenia. The biotech aims to advance neuropsychiatric treatments with this substantial financial backing.
Merck & Co. decides against licensing Evaxion's gonorrhea vaccine, ending potential $592M deal. Danish biotech now exploring new partnerships for vaccine development after Merck's exit.
December 21, 2025 at 8:00 PM
Merck & Co. decides against licensing Evaxion's gonorrhea vaccine, ending potential $592M deal. Danish biotech now exploring new partnerships for vaccine development after Merck's exit.
Aditum Bio, founded by former Novartis executives, partners with Fosun in China for new drug development company. The collaboration is set to drive innovative treatments in the biotech space.
December 21, 2025 at 1:02 PM
Aditum Bio, founded by former Novartis executives, partners with Fosun in China for new drug development company. The collaboration is set to drive innovative treatments in the biotech space.
🚀 Cybin rebrands to Helus Pharma for Nasdaq listing. Name change part of strategic shift to new stock exchange. Exciting times ahead for the company!
December 20, 2025 at 10:00 PM
🚀 Cybin rebrands to Helus Pharma for Nasdaq listing. Name change part of strategic shift to new stock exchange. Exciting times ahead for the company!
🌟 Aditum Bio, founded by ex-Novartis execs Joe Jimenez and Mark Fishman, strikes major collaboration with Fosun in China. New company to focus on innovative biotech projects. Exciting times ahead in the biotech landscape!
December 20, 2025 at 8:00 PM
🌟 Aditum Bio, founded by ex-Novartis execs Joe Jimenez and Mark Fishman, strikes major collaboration with Fosun in China. New company to focus on innovative biotech projects. Exciting times ahead in the biotech landscape!
Novo's obesity partner hires Pfizer vet as CBO. CureVac's leadership transitions as BioNTech steps in. Exciting changes shake up the biotech world!
December 20, 2025 at 1:00 PM
Novo's obesity partner hires Pfizer vet as CBO. CureVac's leadership transitions as BioNTech steps in. Exciting changes shake up the biotech world!
Nature Biotechnology reveals the impact of vConTACT3, a machine learning tool for hierarchical virus taxonomy. This innovative system allows for the systematic classification of eukaryotic and prokaryotic viruses on a multirank, large scale. Find out more at nature.com
December 19, 2025 at 10:00 PM
Nature Biotechnology reveals the impact of vConTACT3, a machine learning tool for hierarchical virus taxonomy. This innovative system allows for the systematic classification of eukaryotic and prokaryotic viruses on a multirank, large scale. Find out more at nature.com
Merck & Co. opts out of licensing Evaxion's gonorrhea vaccine, leading Danish biotech to lose potential $592M deal. Evaxion now on the lookout for alternative partnerships.
December 19, 2025 at 8:00 PM
Merck & Co. opts out of licensing Evaxion's gonorrhea vaccine, leading Danish biotech to lose potential $592M deal. Evaxion now on the lookout for alternative partnerships.
Nature Biotechnology reports on the development of engineered base editors with improved precision and reduced bystander editing. The study showcases advancements in deaminase and gRNA engineering for more accurate editing.
December 19, 2025 at 1:01 PM
Nature Biotechnology reports on the development of engineered base editors with improved precision and reduced bystander editing. The study showcases advancements in deaminase and gRNA engineering for more accurate editing.
🧬 Engineered base editors achieve enhanced precision with reduced bystander editing through directed evolution. Nature Biotechnology reports the breakthrough online. Deaminase and gRNA modifications drive the advancements.
December 18, 2025 at 10:00 PM
🧬 Engineered base editors achieve enhanced precision with reduced bystander editing through directed evolution. Nature Biotechnology reports the breakthrough online. Deaminase and gRNA modifications drive the advancements.
Empower Pharmacy ceases operations at New Jersey facility and dismisses hundreds of employees. The compounding pharmacy has been under scrutiny for drug quality issues and legal disputes with Eli Lilly.
December 18, 2025 at 8:00 PM
Empower Pharmacy ceases operations at New Jersey facility and dismisses hundreds of employees. The compounding pharmacy has been under scrutiny for drug quality issues and legal disputes with Eli Lilly.
💰 GSK invests $17.5M in partnership with CAMP4 Therapeutics for regulatory RNA-targeting therapeutics in neurodegenerative and kidney diseases. Exciting collaboration aims to advance treatment options in critical health areas.
December 18, 2025 at 1:00 PM
💰 GSK invests $17.5M in partnership with CAMP4 Therapeutics for regulatory RNA-targeting therapeutics in neurodegenerative and kidney diseases. Exciting collaboration aims to advance treatment options in critical health areas.
🔥 Former NIH institute director sues Trump officials over wrongful firing. Alleges violation of rights and illegal ouster under federal whistleblower protections. Seeking reinstatement and backpay.
December 17, 2025 at 10:00 PM
🔥 Former NIH institute director sues Trump officials over wrongful firing. Alleges violation of rights and illegal ouster under federal whistleblower protections. Seeking reinstatement and backpay.
🌟 Breakthrough in cancer immunotherapy: Antibody-lectin chimeras block glyco-immune checkpoints. Nature Biotechnology reports promising results for potential new treatment approach.
December 17, 2025 at 8:00 PM
🌟 Breakthrough in cancer immunotherapy: Antibody-lectin chimeras block glyco-immune checkpoints. Nature Biotechnology reports promising results for potential new treatment approach.
California-based Ambros Therapeutics secures $125 million in funding to bring an established pain drug, already approved in Italy, to the US market. The company emerges with strong financial backing and industry veteran Vivek Ramaswamy on board.
December 17, 2025 at 1:00 PM
California-based Ambros Therapeutics secures $125 million in funding to bring an established pain drug, already approved in Italy, to the US market. The company emerges with strong financial backing and industry veteran Vivek Ramaswamy on board.
Antibody-lectin chimeras have demonstrated efficacy in cancer immunotherapy by targeting glyco-immune checkpoints. The study, published in Nature Biotechnology, highlights a novel approach to enhancing treatment outcomes.
December 16, 2025 at 10:00 PM
Antibody-lectin chimeras have demonstrated efficacy in cancer immunotherapy by targeting glyco-immune checkpoints. The study, published in Nature Biotechnology, highlights a novel approach to enhancing treatment outcomes.
🌟 FDA approves Medivis AR headset for neurosurgery navigation, expanding its medical technology reach. Earlier FDA clearance for spine-focused platform sets the stage for cranial navigation system success.
December 16, 2025 at 8:00 PM
🌟 FDA approves Medivis AR headset for neurosurgery navigation, expanding its medical technology reach. Earlier FDA clearance for spine-focused platform sets the stage for cranial navigation system success.
Biotechs Chai and Link raise $130M and $60M respectively in series B funding rounds. The investments will support their expansion and development efforts as they continue to make strides in the biotech sector.
December 16, 2025 at 1:00 PM
Biotechs Chai and Link raise $130M and $60M respectively in series B funding rounds. The investments will support their expansion and development efforts as they continue to make strides in the biotech sector.
🌏 Western genetic medicine makers tap into Chinese investigator-initiated trials trend. Belgian cell therapy startup EsoBiotec, with €22M funding, develops innovative infusion to transform immune cells into disease fighters.
December 15, 2025 at 10:00 PM
🌏 Western genetic medicine makers tap into Chinese investigator-initiated trials trend. Belgian cell therapy startup EsoBiotec, with €22M funding, develops innovative infusion to transform immune cells into disease fighters.